Systemic therapy with the tyrosine kinase inhibitor lenvatinib in six patients with distantly metastatic malignant melanoma

被引：0
|
作者：
Klumpp, A. [1 ]
Stege, H. [1 ]
Lang, B. [1 ]
Grabbe, S. [1 ]
机构：
[1] Univ Mainz Mainz, Hautklin, Mainz, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2023年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
eP076
引用
收藏
页码：76 / 76
页数：1
相关论文
共 50 条
  • [31] SYSTEMIC THERAPY OF MALIGNANT-MELANOMA
    SEEGER, J
    RICHMAN, SP
    ALLEGRA, JC
    MEDICAL CLINICS OF NORTH AMERICA, 1986, 70 (01) : 89 - 94
  • [32] Current systemic therapy for metastatic melanoma
    Agarwala, Sanjiv S.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (05) : 587 - 595
  • [33] Observation prior to systemic therapy in patients with metastatic renal cell carcinoma in the kinase inhibitor era.
    Fisher, R. A.
    Pender, A.
    Thillai, K.
    Chowdhury, S.
    Pickering, L. M.
    Rose, S. St.
    Gore, M. E.
    Larkin, J. M. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] Prediction of morbidity following cytoreductive surgery for metastatic gastrointestinal stromal tumour in patients on tyrosine kinase inhibitor therapy
    Fairweather, M.
    Cavnar, M. J.
    Li, G. Z.
    Bertagnolli, M. M.
    DeMatteo, R. P.
    Raut, C. P.
    BRITISH JOURNAL OF SURGERY, 2018, 105 (06) : 743 - 750
  • [35] Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma
    Susan Burdette-Radoux
    Richard G. Tozer
    Reinhard C. Lohmann
    Ian Quirt
    D. Scott Ernst
    Wendy Walsh
    Nancy Wainman
    A. Dimitrios Colevas
    Elizabeth A. Eisenhauer
    Investigational New Drugs, 2004, 22 : 315 - 322
  • [36] Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma
    Burdette-Radoux, S
    Tozer, RG
    Lohmann, RC
    Quirt, I
    Ernst, DS
    Walsh, W
    Wainman, N
    Colevas, AD
    Eisenhauer, EA
    INVESTIGATIONAL NEW DRUGS, 2004, 22 (03) : 315 - 322
  • [37] Response to Tyrosine Kinase Inhibitor Lenvatinib in a Child with Refractory Papillary Thyroid Carcinoma
    Mahajan, Priya
    Quintanilla, Norma
    Lopez, Monica
    Orth, Robert
    Athanassaki, Ioanna
    Venkatramani, Rajkumar
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S78 - S78
  • [38] Tyrosine kinase inhibitor therapy in pediatric sarcoma: Prognostic implications of pulmonary metastatic cavitation
    Morakote, Wipawee
    Adams, Lisa C.
    Ramasamy, Shakthi K.
    Spunt, Sheri L.
    Baratto, Lucia
    Liang, Tie
    Daldrup-Link, Heike E.
    PEDIATRIC BLOOD & CANCER, 2023,
  • [39] Targeted and Checkpoint Inhibitor Therapy of Metastatic Malignant Melanoma in Germany, 2000-2016
    Hellmund, Peter
    Schmitt, Jochen
    Roessler, Martin
    Meier, Friedegund
    Schoffer, Olaf
    CANCERS, 2020, 12 (09) : 1 - 17
  • [40] INTERLEUKIN-2 THERAPY IN PATIENTS WITH METASTATIC MALIGNANT-MELANOMA
    DORVAL, T
    FRIDMAN, WH
    MATHIOT, C
    SASTRE, X
    POUILLART, P
    BULLETIN DU CANCER, 1992, 79 (08) : 781 - 787
12345